<DOC>
	<DOCNO>NCT02238522</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) ZEN003365 patient relapsed/refractory lymphoproliferative malignancy ( LPM ) relapsed/refractory acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Phase 1 Study Evaluating ZEN003365 Relapsed/Refractory Lymphoproliferative Malignancies Relapsed/Refractory AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Dose Escalation Expansion Stages : ECOG performance status ≤ 1 LPM patient , ≤ 2 AML patient Age 18 year old Adverse event ( AEs ) , except alopecia , previous treatment must recover eligibility level prior toxicity Adequate renal , hepatic coagulation function , specify per protocol Written inform consent grant prior studyspecific screening procedure LPM Patients : Histologically confirm lymphoproliferative malignancy Have receive prior protocolspecified diseasedependent prior treatment Have measurable disease Platelets ≥ 75,000/µL ( ≥50,000/µL bone marrow involvement ) , absolute neutrophil count ( ANC ) ≥ 1,000/ µL , hemoglobin ( Hgb ) ≥ 8 g/dL Patients must previous anticancer therapy least 3 week 5 halflives , whichever longer , subject must recover eligibility level prior toxicity AML : Refractory relapse AML patient , without curative intent , e.g. , stem cell transplant candidate Any prior chemotherapy must complete ≥ 2 week , therapy biologics must complete ≥ 4 week prior day 1 study treatment , participant must recover eligibility level prior toxicity Blast count ≤ 10,000/µL prior initiation therapy Exclusion Criteria Dose Escalation Expansion Stages : Prior exposure BET inhibitor Prior allogeneic hematopoietic cell transplant Chronic graft versus host disease Known , active fungal , bacterial , and/or viral infection Uncontrolled autoimmune hemolytic anemia thrombocytopenia Current subdural hematoma CNS leptomeningeal metastasis Requirement medication agent know sensitive CYP3A4 substrate drug , CYP3A4 substrate drug narrow therapeutic range strong inhibitors/inducers CYP3A4 Requirement immunosuppressive agent Evidence significant cardiovascular disease significant screen ECG abnormality Any medical condition , Investigator 's opinion , would impose excessive risk patient . AML patient : Acute promyelocytic leukemia ( APL ) Chronic myeloid leukemia ( CML ) blast crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>B-prolymphocytic leukemia</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>small lymphocytic lymphoma</keyword>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>unclassifiable lymphoma</keyword>
	<keyword>T-cell lymphoma</keyword>
	<keyword>Richter 's syndrome</keyword>
	<keyword>Waldenström 's macroglobulinemia</keyword>
</DOC>